scanX
Dr Reddys Laboratories
add_icon

Dr Reddys Laboratories

1,249.30
+1.30
(0.10%)
Market Cap
₹1,04,268.30 Cr
PE Ratio
18.15
Volume
10,60,956.00
Day High - Low
₹1,256.00 - ₹1,241.00
52W High-Low
₹1,405.90 - ₹1,020.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,04,268.30 Cr
EPS
67.89
PB Ratio
2.89
Book Value
431.50
EBITDA
9,644.40
Dividend Yield
0.64 %
Industry
Healthcare
Sector
Pharmaceuticals
ROE Growth %
-
Debt to Equity
0.11
Analyst Rating and Forecast
- By Refinitiv from38 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+34.21 %
+34.21 %
Hold
Hold+31.58 %
+31.58 %
Sell
Sell+34.21 %
+34.21 %
Forecast For
Actual

Company News

View All News
Caret
negative
Dr. Reddy's Subsidiary Aurigene Oncology Receives GST Tax Demand Order with Rs. 3.47 Lakh Penalty1 day ago
Aurigene Oncology Limited, a wholly owned subsidiary of Dr. Reddy's Laboratories, received an order from GST Appellate Authority imposing a penalty of Rs. 3,46,998 for alleged short payment of output tax and excess claim of input tax credit. Dr. Reddy's stated there is no material impact on the company's financials or operations and will evaluate filing an appeal against the order.
positive
Dr. Reddy's Receives European Commission Approval for Denosumab Biosimilar3 days ago
Dr. Reddy's has obtained European Commission approval for AVT03 (Denosumab), a proposed biosimilar of Prolia® and Xgeva®. This regulatory approval allows the pharmaceutical company to market its biosimilar version in European markets.
positive
Dr. Reddy's Srikakulam API Plant Passes USFDA Inspection Without DeficienciesNov 14, 2025
Dr. Reddy's Srikakulam API manufacturing plant successfully cleared a USFDA GMP inspection with zero observations. This regulatory clearance affects the pharmaceutical company's ability to continue manufacturing and supplying API products to US markets without compliance issues.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,810.30
#1 4,34,351.60
40.68
#1 54,729.00
9.71
#1 10,980
2.89
76.30
Divis Laboratories
6,490.50
1,72,302.40
69.05
9,712.00
18.67
2,191
35.10
50.50
Torrent Pharmaceuticals
3,730.40
1,26,253.70
58.80
11,539.40
6.99
1,911
30.46
54.46
Cipla
1,525.20
1,23,198.70
22.73
28,409.50
7.12
5,291
3.71
48.61
Dr Reddys Laboratories
1,249.30
#5 1,04,268.30
#1 18.15
#2 33,741.20
#4 16.73
#2 5,725
#9 -0.38
53.75
Lupin
2,071.40
94,612.10
21.34
22,909.50
13.74
3,306
#1 72.75
63.44
Zydus Life Science
937.25
94,309.30
18.56
23,511.00
18.55
4,615
34.60
41.16
Mankind Pharma
2,249.30
92,841.80
52.05
12,744.20
#1 20.90
2,007
-21.05
38.34
Aurobindo Pharma
1,235.80
71,775.50
20.70
32,345.60
9.43
3,484
3.81
67.24
Alkem Laboratories
5,686.50
67,990.60
28.29
13,458.30
3.70
2,216
10.98
53.98

Automatic Screeners on ScanX

Community
Day 1 Unusual Volume
Community
Resistance 1 Breached
Growth Rate
Revenue Growth
16.73 %
Net Income Growth
2.64 %
Cash Flow Change
2.19 %
ROE
-14.54 %
ROCE
-13.11 %
EBITDA Margin (Avg.)
-6.42 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
3,887
3,813
4,061
4,030
3,841
3,302
3,630
3,747
3,575
3,354
3,578
3,849
3,580
3,779
3,937
3,961
4,116
4,290
4,867
4,469
4,516
4,512
4,955
5,015
4,829
5,044
5,993
5,394
5,569
6,079
6,361
6,835
6,443
6,917
7,199
7,434
7,284
7,866
8,330
8,513
9,034
8,836
9,135
Expenses
3,271
2,765
2,888
2,996
3,313
2,855
2,989
2,859
3,021
3,010
2,890
3,041
2,990
2,968
3,058
3,060
3,211
3,117
3,749
4,686
3,500
3,305
3,755
4,403
3,715
4,211
4,427
4,123
5,024
4,292
4,433
4,851
4,781
4,696
4,894
5,214
5,283
5,566
5,962
6,108
6,531
6,399
6,818
EBITDA
616
1,048
1,173
1,034
528
447
640
888
553
344
687
808
590
812
879
901
905
1,174
1,118
-217
1,016
1,207
1,200
613
1,114
833
1,566
1,271
545
1,787
1,928
1,983
1,662
2,221
2,305
2,220
2,001
2,300
2,368
2,405
2,503
2,437
2,317
Operating Profit %
15 %
26 %
28 %
25 %
12 %
12 %
17 %
23 %
15 %
9 %
18 %
20 %
15 %
20 %
19 %
21 %
20 %
19 %
22 %
-7 %
21 %
25 %
23 %
11 %
21 %
14 %
23 %
23 %
8 %
18 %
30 %
28 %
24 %
30 %
29 %
28 %
25 %
27 %
26 %
27 %
23 %
25 %
23 %
Depreciation
0
203
224
235
277
244
262
267
254
259
270
272
276
279
279
290
287
289
313
287
274
292
317
311
309
284
294
294
293
302
309
324
316
353
376
374
368
381
397
471
455
476
505
Interest
23
28
22
16
17
15
13
16
20
22
22
17
18
20
21
24
25
30
30
15
23
23
25
19
30
19
23
22
32
35
31
42
35
37
35
39
59
60
76
82
66
83
91
Profit Before Tax
593
831
960
733
273
199
396
622
337
81
409
547
314
529
599
601
606
869
786
-506
736
901
873
295
815
556
1,273
974
259
1,468
1,614
1,638
1,329
1,850
1,917
1,829
1,605
1,883
1,917
1,874
2,005
1,905
1,745
Tax
74
184
185
147
150
45
87
130
-1
14
103
244
42
53
81
101
151
193
-321
33
-45
306
101
267
258
175
277
265
162
279
499
394
369
445
435
448
295
490
576
470
419
495
408
Net Profit
519
647
775
586
123
154
309
492
338
67
305
303
272
476
518
500
455
677
1,107
-538
781
595
772
28
557
380
996
709
97
1,189
1,114
1,244
960
1,405
1,482
1,381
1,310
1,392
1,342
1,404
1,587
1,410
1,337
EPS in ₹
30.45
37.99
45.42
34.34
7.19
9.06
18.64
29.72
20.38
4.02
18.42
18.25
16.39
28.69
31.22
30.16
27.45
40.81
66.78
-32.48
47.12
35.87
46.54
1.68
33.61
22.95
60.03
42.75
5.84
71.64
67.13
74.91
57.79
84.55
89.09
82.94
78.66
83.61
75.40
16.97
19.12
17.04
16.18
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
18,598
20,384
21,817
22,544
22,466
23,225
26,617
29,747
32,285
38,864
49,427
Fixed Assets
5,377
6,563
6,931
6,968
7,191
6,850
8,206
8,122
9,219
10,426
18,226
Current Assets
11,877
11,794
9,684
10,498
11,110
12,599
14,550
17,782
20,426
24,805
25,018
Capital Work in Progress
529
772
3,325
3,471
2,934
1,535
1,565
1,293
1,030
1,419
2,466
Investments
2,102
3,833
2,110
2,298
2,587
2,678
2,212
2,616
4,986
4,931
4,051
Other Assets
10,590
9,216
9,452
9,808
9,754
12,162
14,634
17,716
17,050
22,088
24,684
Total Liabilities
18,598
20,384
21,817
22,544
22,466
23,225
26,617
29,747
32,285
38,864
49,427
Current Liabilities
6,821
6,347
8,420
6,894
5,897
7,214
8,104
9,766
8,572
9,588
13,034
Non Current Liabilities
1,923
1,467
1,135
3,079
2,545
412
871
769
427
1,021
2,465
Total Equity
9,853
12,570
12,262
12,572
14,024
15,599
17,642
19,212
23,286
28,255
33,927
Reserve & Surplus
9,768
12,485
12,179
12,489
13,994
15,616
17,755
19,289
23,330
28,171
33,466
Share Capital
85
85
83
83
83
83
83
83
83
83
83
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-280
-47
-114
-124
-31
-27
1,286
3
-907
133
749
Investing Activities
-2,370
-1,610
-1,890
-1,483
-769
-495
-2,255
-2,565
-4,109
-4,034
-5,785
Operating Activities
2,524
3,263
2,144
1,803
2,870
2,984
3,570
2,811
5,888
4,543
4,643
Financing Activities
-433
-1,700
-369
-444
-2,133
-2,516
-30
-242
-2,686
-376
1,891
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
26.74 %
26.73 %
26.72 %
26.72 %
26.72 %
26.71 %
26.71 %
26.70 %
26.70 %
26.69 %
26.66 %
26.65 %
26.65 %
26.65 %
26.64 %
26.64 %
26.64 %
26.64 %
26.64 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
42.21 %
0.00 %
44.49 %
42.27 %
41.75 %
40.08 %
37.29 %
36.36 %
35.52 %
DIIs
14.25 %
15.08 %
20.92 %
21.95 %
24.46 %
24.95 %
24.47 %
23.38 %
23.05 %
21.99 %
21.04 %
16.21 %
18.31 %
20.73 %
21.48 %
22.90 %
25.62 %
26.74 %
27.98 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.31 %
7.76 %
8.14 %
8.27 %
8.37 %
8.22 %
8.06 %
7.84 %
7.59 %
7.51 %
7.91 %
8.44 %
8.25 %
8.07 %
8.07 %
8.07 %
8.20 %
8.04 %
7.56 %
Others
50.70 %
50.43 %
44.22 %
43.07 %
40.45 %
40.12 %
40.76 %
42.08 %
42.66 %
43.80 %
2.18 %
48.69 %
2.30 %
2.29 %
2.06 %
2.30 %
2.25 %
2.22 %
2.30 %
No of Share Holders
2,21,107
2,23,309
2,55,720
2,42,376
2,63,803
2,55,300
2,59,271
2,46,788
2,32,715
2,46,769
2,43,445
2,57,794
2,55,500
2,67,694
3,10,403
4,03,669
4,59,605
4,51,929
4,49,216

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 20 20 20 20 25 25 30 40 40 8
Dividend Yield (%) 3.8 4.81 3.6 3.2 2.77 2.91 3.24 3.25 3.5 0.64

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Jul 2021 DIVIDEND Dividend
₹ 25.00 /share
 09 Jul 2021 1,060.40 1,097.91
13 Jul 2022 DIVIDEND Dividend
₹ 30.00 /share
 11 Jul 2022 781.62 896.74
12 Jul 2023 DIVIDEND Dividend
₹ 40.00 /share
 11 Jul 2023 986.65 1,033.17
17 Jul 2024 DIVIDEND Dividend
₹ 40.00 /share
 16 Jul 2024 1,258.69 1,329.21
29 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Jul 2024 1,258.69 1,378.43
27 Jul 2024 SPLIT Split
1:5
 28 Oct 2024 1,378.43 1,378.43
05 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Nov 2024 1,310.23 1,268.30
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 Jan 2025 1,343.65 1,296.25
09 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 09 May 2025 1,187.20 1,148.00
10 Jul 2025 DIVIDEND Dividend
₹ 8.00 /share
 10 Jul 2025 1,148.00 1,269.40
23 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 Jul 2025 1,325.45 1,240.40
24 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 24 Jul 2025 1,148.00 1,247.40
24 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Oct 2025 1,321.70 1,279.40

Announcements

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 20151 day ago
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 20151 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication9 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Nov 14, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 13, 2025
Reply To Clarification Sought By BSENov 11, 2025
Clarification sought from Dr Reddys Laboratories LtdNov 10, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementNov 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 30, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 Oct 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 25, 2025
Announcement Under Regulation 30 - Earnings Call RecordingsOct 25, 2025
Announcement Under Regulation 30 - Update On Senior Management PersonnelOct 24, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationOct 24, 2025
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Oct 24, 2025
Board Meeting Outcome for Outcome Of Board MeetingOct 24, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Oct 21, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Oct 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 22, 2025
Closure of Trading WindowSep 22, 2025
Board Meeting Intimation for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending On September 30 2025Sep 22, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 19, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Sep 19, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Sep 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 15, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 13, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Sep 10, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 06, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 05, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements)Regulations 2015Sep 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 01, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 29, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 Aug 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Announcement Under Regulation 30 Of SEBI LODR Regulations 2015 - UpdatesAug 08, 2025
Announcement Under Regulation 30 - UpdatesAug 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Value Direct-Growth
2.45%
2522914
0.39%
0.26%
Quant ELSS Tax Saver Fund Direct-Growth
0.00%
-2080408
-2.15%
-2.30%
Tata Value Fund Direct-Growth
0.00%
-1778619
-2.55%
-2.68%
ICICI Prudential Equity & Debt Fund Direct-Growth
0.56%
1199054
0.28%
0.27%
UTI Large Cap Fund Direct-Growth
0.00%
-1096170
-1.04%
-1.09%
ICICI Prudential Equity Savings Fund Direct-Growth
1.35%
814206
0.53%
0.48%
Parag Parikh Flexi Cap Fund Direct-Growth
1.22%
667602
-0.02%
-0.06%
NJ Balanced Advantage Fund Direct - Growth
1.72%
542851
1.72%
1.72%
NJ Flexi Cap Fund Direct - Growth
2.56%
520499
2.56%
2.56%
ICICI Prudential Balanced Advantage Direct-Growth
0.77%
-474335
-0.12%
-0.17%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
9.42%
431596
0.32%
-0.05%
Mirae Asset ELSS Tax Saver Fund Direct-Growth
1.43%
425000
0.10%
0.05%
UTI Aggressive Hybrid Fund Direct Fund-Growth
0.00%
-422338
-0.81%
-0.84%
UTI Large & Mid Cap Fund Direct-Growth
0.27%
-418663
-1.05%
-1.12%
HDFC Multi Cap Fund Direct - Growth
0.00%
-395500
-0.26%
-0.27%
Mirae Asset Large Cap Fund Direct- Growth
0.71%
360409
0.07%
0.05%
Bandhan Flexi Cap Fund Direct-Growth
1.10%
250000
0.35%
0.33%
Tata Large & Mid Cap Fund Direct Plan-Growth
0.00%
-250000
-0.36%
-0.37%
Mirae Asset Large & Midcap Fund Direct-Growth
1.09%
250000
-0.01%
-0.06%
JM Flexicap Fund Direct Plan-Growth
0.49%
250000
0.49%
0.49%
Nippon India Flexi Cap Fund Direct - Growth
0.69%
200000
0.23%
0.20%
ICICI Prudential Large & Mid Cap Fund Direct Plan-Growth
0.35%
-187500
-0.12%
-0.15%
Kotak Quant Fund Direct - Growth
3.49%
120869
2.51%
3.49%
PGIM India Flexi Cap Fund Direct-Growth
0.68%
-108000
-0.25%
-0.27%
Mirae Asset Flexi Cap Fund Direct - Growth
0.58%
-108000
-0.48%
-0.54%

Technical Indicators

RSI(14)
Neutral
53.75
ATR(14)
Less Volatile
21.10
STOCH(9,6)
Neutral
61.55
STOCH RSI(14)
Overbought
87.50
MACD(12,26)
Bullish
3.23
ADX(14)
Weak Trend
13.57
UO(9)
Bearish
50.10
ROC(12)
Uptrend But Slowing Down
3.12
WillR(14)
Overbought
-19.44
Bearish
5
Neutral
3
Bullish
1
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104